2,072
Views
6
CrossRef citations to date
0
Altmetric
Editorial

Immunotherapy for non-small cell lung cancer: are we on the cusp of a new era?

&

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Articles from other publishers (5)

Roza Nurieva, Margarita Divenko & Sang Kim. 2021. Rheumatic Diseases and Syndromes Induced by Cancer Immunotherapy. Rheumatic Diseases and Syndromes Induced by Cancer Immunotherapy 3 29 .
Rui Cao, Jie‐Tao Ma, Shu‐Ling Zhang, Li Sun, Yang Liu, Xiang‐Yan Zhang, Wei Jing, Le‐Tian Huang & Cheng‐Bo Han. (2019) Rational application of the first‐line chemotherapy and immune checkpoint inhibitors in advanced nonsmall cell lung cancer: A meta‐analysis. Cancer Medicine 8:11, pages 5033-5046.
Crossref
Ling Ni & Chen Dong. (2017) New checkpoints in cancer immunotherapy. Immunological Reviews 276:1, pages 52-65.
Crossref
Guangfu Li, Dai Liu, Timothy K. Cooper, Eric T. Kimchi, Xiaoqiang Qi, Diego M. Avella, Ningfei Li, Qing X. Yang, Mark Kester, C. Bart Rountree, Jussuf T. Kaifi, David J. Cole, Don C. Rockey, Todd D. Schell & Kevin F. Staveley-O’Carroll. (2017) Successful chemoimmunotherapy against hepatocellular cancer in a novel murine model. Journal of Hepatology 66:1, pages 75-85.
Crossref
Erika Schneble, G. Travis Clifton, Diane F. Hale & George E. Peoples. 2016. Vaccine Design. Vaccine Design 797 817 .

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.